With its lead therapy in a late-stage obesity trial, Arena Pharmaceuticals announced that it has nailed down an equity financing commitment of up to $50 million from Azimuth Opportunity. Over the 18-month term of the deal Arena can sell new shares of common stock to Azimuth at a previously negotiated discount. Report